This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2005.11.073v1 47/8/1576    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Al-Mallah, M. H. Articles by Weaver, W. D. Search for Related Content PubMed PubMed Citation Articles by Al-Mallah, M. H. Articles by Weaver, W. D.

CLINICAL RESEARCH: CORONARY ARTERY DISEASE

Angiotensin-Converting Enzyme Inhibitors in Coronary Artery Disease and Preserved Left Ventricular Systolic Function

A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Mouaz H. Al-Mallah, MD^_*,_*, Imad M. Tleyjeh, MD, Ahmed A. Abdel-Latif, MD and W. Douglas Weaver, MDFACC^_*

^_* Division of Cardiology, Henry Ford Heart and Vascular Institute, Detroit, Michigan
Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota
Division of Cardiology, University of Louisville, Louisville, Kentucky

Manuscript received August 2, 2005; revised manuscript received November 22, 2005, accepted November 28, 2005.

^_* Reprint requests and correspondence: Dr. Mouaz Al-Mallah, Henry Ford Heart and Vascular Institute, 2799 West Grand Boulevard, K 14, Detroit, Michigan 48202 (Email: malmall1{at}hfhs.org).

OBJECTIVES: This study sought to assess the efficacy of angiotensin-converting enzyme inhibitors (ACEIs) in patients with coronary heart disease and preserved left ventricular (LV) function.

BACKGROUND: The ACEIs have been shown to improve outcomes in patients with heart failure and myocardial infarction (MI). However, there is conflicting evidence concerning the benefits of ACEIs in patients with coronary artery disease (CAD) and preserved LV systolic function.

METHODS: An extensive search was performed to identify randomized, placebo-controlled trials of ACEI use in patients with CAD and preserved LV systolic function. Of 61 potentially relevant articles screened, 6 trials met the inclusion criteria. They were reviewed to determine cardiovascular mortality, nonfatal MI, all-cause mortality, and revascularization rates. We performed random-effect model meta-analyses and quantified between-studies heterogeneity with I².

RESULTS: There were 16,772 patients randomized to ACEI and 16,728 patients randomized to placebo. Use of ACEIs was associated with a decrease in cardiovascular mortality (relative risk [RR] 0.83, 95% confidence interval [CI] 0.72 to 0.96, p = 0.01), nonfatal MI (RR 0.84, 95% CI 0.75 to 0.94, p = 0.003), all-cause mortality (RR 0.87, 95% CI 0.81 to 0.94, p = 0.0003), and revascularization rates (RR 0.93, 95% CI 0.87 to 1.00, p = 0.04). There was no significant between-studies heterogeneity. Treatment of 100 patients for an average duration of 4.4 years prevents either of the adverse outcomes (one death, or one nonfatal myocardial infarction, or one cardiovascular death or one coronary revascularization procedure).

CONCLUSIONS: The cumulative evidence provided by this meta-analysis shows a modest favorable effect of ACEIs on the outcome of patients with CAD and preserved LV systolic function.

Abbreviations and Acronyms   ACEI = angiotensin-converting enzyme inhibitor   CAD = coronary artery disease   LV = left ventricular   MI = myocardial infarction   PCI = percutaneous coronary intervention

This article has been cited by other articles:

				D. J. Maron, W. E. Boden, R. A. O'Rourke, P. M. Hartigan, K. J. Calfas, G.B. J. Mancini, J. A. Spertus, M. Dada, W. J. Kostuk, M. Knudtson, et al. Intensive Multifactorial Intervention for Stable Coronary Artery Disease: Optimal Medical Therapy in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) Trial J. Am. Coll. Cardiol., March 30, 2010; 55(13): 1348 - 1358. [Abstract] [Full Text] [PDF]

				S. J. Corbett, N. Curzen, and K. F. Fox Chapter 26 Optimal medical therapy in percutaneous coronary intervention patients: statins and ACE inhibitors as disease-modifying agents Oxford Textbook of Interventional Cardiology, January 1, 2010; 1(1): med-9780199569083-chapter - med-9780199569083-chapter. [Abstract] [Full Text]

				W. L. Baker, C. I. Coleman, J. Kluger, K. M. Reinhart, R. Talati, R. Quercia, O. J. Phung, and C. M. White Systematic Review: Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II-Receptor Blockers for Ischemic Heart Disease Ann Intern Med, December 15, 2009; 151(12): 861 - 871. [Abstract] [Full Text] [PDF]

				J. J. Brugts, T. Ninomiya, E. Boersma, W. J. Remme, M. Bertrand, R. Ferrari, K. Fox, S. MacMahon, J. Chalmers, and M. L. Simoons The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials Eur. Heart J., June 1, 2009; 30(11): 1385 - 1394. [Abstract] [Full Text] [PDF]

				Authors/Task Force Members, F. Van de Werf, J. Bax, A. Betriu, C. Blomstrom-Lundqvist, F. Crea, V. Falk, G. Filippatos, K. Fox, K. Huber, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology: Eur. Heart J., December 1, 2008; 29(23): 2909 - 2945. [Full Text] [PDF]

				D. L. Ngaage, S. Griffin, L. Guvendik, M. E. Cowen, and A. R.J. Cale Changing Operative Characteristics of Patients Undergoing Operations for Coronary Artery Disease: Impact on Early Outcomes Ann. Thorac. Surg., November 1, 2008; 86(5): 1424 - 1430. [Abstract] [Full Text] [PDF]

				J. Bauersachs and D. Fraccarollo More NO-No More ROS: Combined Selective Mineralocorticoid Receptor Blockade and Angiotensin-Converting Enzyme Inhibition for Vascular Protection Hypertension, March 1, 2008; 51(3): 624 - 625. [Full Text] [PDF]

				L. H. Curtis, D. J. Whellan, B. G. Hammill, A. F. Hernandez, K. J. Anstrom, A. M. Shea, and K. A. Schulman Incidence and Prevalence of Heart Failure in Elderly Persons, 1994-2003 Arch Intern Med, February 25, 2008; 168(4): 418 - 424. [Abstract] [Full Text] [PDF]

				D. M Shavelle Long term medical treatment of stable coronary disease Heart, November 1, 2007; 93(11): 1473 - 1477. [Full Text] [PDF]

				S. Heeneman, J. C. Sluimer, and M. J.A.P. Daemen Angiotensin-Converting Enzyme and Vascular Remodeling Circ. Res., August 31, 2007; 101(5): 441 - 454. [Abstract] [Full Text] [PDF]

				C. D Bubbar, D. F Blackburn, M. P Wilson, and T. W Wilson Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Hypertension Due to Primary Aldosteronism: A Case for Exclusion Ann. Pharmacother., January 1, 2007; 41(1): 129 - 132. [Abstract] [Full Text] [PDF]

				K. Fox, R. Ferrari, S. Yusuf, and J. S. Borer Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function? Eur. Heart J., September 2, 2006; 27(18): 2154 - 2157. [Abstract] [Full Text] [PDF]

				P. A. McCullough Chronic Kidney Disease: Tipping the Scale to the Benefit of Angiotensin-Converting Enzyme Inhibitors in Patients With Coronary Artery Disease Circulation, July 4, 2006; 114(1): 6 - 7. [Full Text] [PDF]

				ACE Inhibitors in Coronary Artery Disease Patients with Preserved LV Function Journal Watch Emergency Medicine, June 13, 2006; 2006(613): 6 - 6. [Full Text]